Clinical Profile Of Hepatocellular Carcinoma-Experience At A Tertiary Care Hospital
DOI:
https://doi.org/10.51985/JBUMDC2019087Abstract
Objective: To determine the characteristics of Hepatocellular carcinoma (HCC) in patients visiting PEMH Rawalpindi.
Study Design and Setting: Cross-sectional Study conducted at Department of Gastroenterology/hepatology in Pak Emirates
Military Hospital Rawalpindi (PEMH) from Oct 2015 to Jan 2018.
Methodology: In this study total 100 patients, with HCC of both genders were included. All the cases were discussed in
multidisciplinary team (MDT) meetings which were held once every week. A decision on the best possible management
for the given case was arrived at in the MDT meeting. All the relevant features of each case were recorded in the Performa.
Descriptive statistics were used to calculate mean, standard deviation and frequencies for gender, various presenting features,
co-morbidities and clinical features. Data was analyzed on SPSS version 21. P value <0.05 was considered as statistically
significant.
Results: Sixty seven men and 33 women with HCC were included in this study with a mean age of 58.23 years. The
abdominal pain was the most common symptom present in 66 (66%) patients. Edema was seen in 30 (30%) and palpable
splenomegaly in 26(26%). Diabetes mellitus was the most common co-morbidity found in 20(20%) patients. HCV was
the commonest cause of HCC present in 79(79%) patients. Vascular involvement was seen in 15 (15%) patients. Most
(62%) patients had a single HCC lesion and most belonged to Child –Pugh class A (68%) and BCLC stage B (42%). ECOG
performance status was good in most patients with 49% patients scoring 0. The AFP levels were raised in 58 (58%) of the
patients.
Conclusion: HCV was the most common underlying etiology. Most of the patients were asymptomatic at the time of
diagnosis. Majority of subjects reported with the complaint of abdominal pain and had no underlying co morbidity. The
metastasis was negative in majority of cases.
References
McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19(2):223-38.
Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017;152(4):745-61.
Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22(3):141-50.
Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterology Research and Practice. 2016;2016:10.
Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2018;27(3):205-12
Butt AS, Abbas Z, Jafri W. Hepatocellular carcinoma in pakistan: where do we stand? Hepat Mon. 2012;12(10 HCC):e6023-e
Butt AS, Hamid S, Wadalawala AA, Ghufran M, Javed AA, Farooq O, et al. Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral- hepatocellular carcinoma. BMC research notes. 2013;6(1):137.
Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. J Clin Gastroenterol. 2019.
Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184-90.
Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology (Baltimore, Md). 2015;61(1):184-90.
Khokhar N, Aijazi I, Gill ML. Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. Journal of Ayub Medical College Abbottabad. 2003;15(4)
https://www .calculator .net/sample-size- calculator.html?type=1&cl=95&ci=5&pp=5.20&ps=&x=78 &y=14
Liu P, Xie S-H, Hu S, Cheng X, Gao T, Zhang C, et al. Age- specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget. 2017;8(40):68131- 7.
Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for hepatocellular carcinoma? J Hepatol. 2012;57(2):453-4.
Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases. QJM : monthly journal of the Association of Physicians. 2008;101(6):479-85.
Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S et al. Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015; 6:394-402
Wu G, Wu J, Wang B, Zhu X, Shi X, Ding Y. Importance of tumor size at diagnosis as a prognostic factor for hepatocellular carcinoma survival: a population-based study. Cancer Manag Res. 2018;10:4401-10.
Dai CY, Lin CY, Tsai PC, Lin PY, Yeh ML, Huang CF, et al. Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. Journal of the Chinese Medical Association: JCMA. 2018;81(2):155- 63.
Truant S, Boleslawski E, Duhamel A, Bouras AF, Louvet A, Febvay C, et al. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2012;38(12):1189-96
Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, et al. Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. J Cancer. 2015;6(4):394-402.
Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology (Baltimore, Md). 2013;57(1):112-9
Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, et al. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clinica chimica acta; international journal of clinical chemistry. 2016;463:39-44.
An SL, Xiao T, Wang LM, Rong WQ, Wu F, Feng L, et al. Prognostic Significance of Preoperative Serum Alpha- fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China. Asian Pacific journal of cancer prevention : APJCP. 2015;16(10):4421-7
ai D-S, Zhang C, Chen P, Jin S-J, Jiang G-Q. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870-.
Lee YH, Hsu CY, Huang YH, Hsia CY, Chiou YY, Su CW, et al. Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. Journal of clinical gastroenterology. 2014;48(8):734-41.
Hsieh C-H, Wei C-K, Yin W-Y, Chang C-M, Tsai S-J, Wang L-Y, et al. Vascular invasion affects survival in early hepatocellular carcinoma. Mol Clin Oncol. 2015;3(1):252-6.
Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver international: official journal of the International Association for the Study of the Liver. 2015;35(9):2155-66.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Rafi ud din, Fauzia Anjum, Abdul Latif Khattak, Rao Saad Ali Khan, Khawar Shabbir, Abdul Latif Khattak
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0